Concepedia

Author

Bruce L. Levine

University of PennsylvaniaORCID

Also Known As

B L Levine, B Levine, B. L. Levine, B. Levine, B.L. Levine, BRUCE L. LEVINE, BRUCE LUBOTSKY LEVINE, Bruce J. Levine, Bruce L Levine, Bruce L. Levine

544

Publications

65.8K

Citations

102

H-Index

182

Concepts

All Affiliations

University of PennsylvaniaChildren's Hospital of PhiladelphiaUPMC Hillman Cancer CenterNovartis (United States)Cancer Research Institute
BL

About

Bruce L. Levine is an author at University of Pennsylvania specializing in medicine, immunology, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

6

6

229

2

Engineering

4

4

569

3

Education

2

2

45

4

Business

1

1

34

5

Humanities

1

1

25

Bruce L. Levine

×

220

Publications

61.4K

Citations

94

H-Index

YearCitations

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner,

New England Journal of Medicine

2018

5.4K

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw,

New England Journal of Medicine

2014

5.3K

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

David L. Porter, Bruce L. Levine, Michael Kalos,

New England Journal of Medicine

2011

3.5K

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Stephan A. Grupp, Michael Kalos, David M. Barrett,

New England Journal of Medicine

2013

3.4K

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Michael Kalos, Bruce L. Levine, David L. Porter,

Science Translational Medicine

2011

2.4K

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Stephen J. Schuster, Jakub Svoboda, Elise A. Chong,

New England Journal of Medicine

2017

1.8K

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai,

Science Translational Medicine

2017

1.7K

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

David Porter, Wei‐Ting Hwang, Noelle V. Frey,

Science Translational Medicine

2015

1.7K

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando,

Nature Medicine

2018

1.7K

CRISPR-engineered T cells in patients with refractory cancer

Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis,

Science

2020

1.4K

Page 1